Jettie Leger, APRN
Family · Salina, KSNPI 1659983575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,168, 2.0 times the $1,064 reported in 2021. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$942
- Pfizer$654
- Amgen$517
- AstraZeneca$381
- plus $1K from 27 others
What the payments were for
- Food & beverage$5,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 89 | $1,168 |
| AbbVie | 85 | $1,080 |
| Lilly USA, LLC | 56 | $942 |
| Pfizer | 51 | $654 |
| Amgen | 33 | $517 |
| AstraZeneca | 16 | $381 |
| Novartis | 8 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $124 |
| Jazz Pharmaceuticals Inc. | 5 | $79 |
| Phathom Pharmaceuticals, Inc. | 7 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Eisai Inc. | 4 | $64 |
| Boehringer Ingelheim | 3 | $55 |
| GSK | 3 | $46 |
| Dexcom, Inc. | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Collegium Pharmaceutical, Inc. | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Merck | 2 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Radius Health, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Vertex | 1 | $20 |
| Si-bone, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,892 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 80 | $79,566 |
| EliquisApixaban | 85 | $66,624 |
| FarxigaDapagliflozin Propanediol | 56 | $51,196 |
| OzempicSemaglutide | 33 | $36,562 |
| TrulicityDulaglutide | 16 | $16,345 |
| KerendiaFinerenone | 17 | $11,020 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,122 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $3,225 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,863 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $1,718 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 75 | $1,632 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 14 | $1,566 |
| Memantine Hcl | 15 | $1,430 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,380 |
| Metformin Hcl ErMetformin Hcl | 55 | $1,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $942 | $95,91196 claims |
| PfizerEliquis | $654 | $66,62485 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $381 | $61,31872 claims |
| Novo NordiskOzempic | $1,168 | $36,56233 claims |
| BayerKerendia | $21 | $11,02017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Salina
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.